Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
- CYB004, a deuterated dimethyltryptamine (“dDMT”) molecule, has potential to overcome existing limitations of DMT and is protected by a composition of matter patent through 2041 – -- Parts A and B of Phase 1 study complete; Part C to determine saf